TITLE

Merck crafts targeted buy with 'Parade.'

AUTHOR(S)
Goetzl, David
PUB. DATE
October 1999
SOURCE
Advertising Age;10/18/1999, Vol. 70 Issue 10, p32
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
This article reports on the target marketing deal between Merck & Co. and Parade Publications as of October 1999. Merck has entered into a deal with Parade Publications to run advertisements in Parade in markets with significant populations of people age 50 and older in the U.S. The program began in September with an unbranded advertisement for osteoporosis drug Fosamax, aimed at women 50 years old and above. It ran in approximately 50 of Parade's 334 markets with a circulation of approximately 15 million; Parade has a total circulation of 37 million. The campaign encourages women in the age group to ask their doctor about a bone density test. Merck is hoping that it will lead to an increase in Fosamax prescriptions. Ellen Oppenheim, senior vice president and media director at FCB Worldwide, hatched the concept of the target marketing campaign.
ACCESSION #
2381653

 

Related Articles

  • HOW ARE PUBLISHERS RESPONDING TO THE SHIFTING MEDIA BUYING CLIMATE?  // Circulation Management;Jan2003, Vol. 18 Issue 1, p38 

    Interviews Music Publishers' Association executive vice president and chief marketing officer Ellen Oppenheim on the magazine's effectiveness as an advertising medium. Increase in the magazine advertising revenue; Comparison between magazine and broadcast media; Basis for planning and buying...

  • Trying Times. Granatstein, Lisa // MediaWeek;7/14/2003, Vol. 13 Issue 27, p30 

    Reports on the decline in the total advertisement pages in the U.S. magazine industry for June 2003 according to the Publishers Information Bureau. Comments from Ellen Oppenheim, executive vice president and chief marketing officer of the Magazine Publishers of America; Total magazine revenue;...

  • Feds subpoena Merck on 3 drugs. M. I. // Medical Marketing & Media;Sep2011, Vol. 46 Issue 9, p10 

    The article reports that Merck & Co. Inc. in the U.S. has received a subpoena related to marketing and selling activities with respect to three drugs namely Temodar, PegIntron and Intron A.

  • On Target. Masterton, John // MediaWeek;03/08/99, Vol. 9 Issue 10, SPECIAL REPORT CONSUMER MAGAZINES p10 

    Focuses on the use of target marketing and special editions of magazines in the United States. Sales range of `Time' for its special editions; How target marketing and special editions can be effective; Details on `Reader's Digest' target advertisement strategy.

  • GROUP METAPHYSICS. Heather, Rosemary // C: International Contemporary Art;Summer2005, Issue 86, p5 

    The article introduces the issue and the desicion making by the promotion company Group Metaphyisc in choosing the market targeted advertising within the magazine.

  • West Point steps out.  // Drug Topics;5/23/94, Vol. 138 Issue 10, p64 

    Reports on West Point Pharma's plans for expanding its generic drug line by marketing generic versions of off-patent drugs originated by pharmaceutical companies other than Merck.

  • State wins case against Merck. Jacklet, Ben // Oregon Business Magazine;Jul2008, Vol. 31 Issue 7, p20 

    The article reports that Oregon has received more than $8.5 million on winning a court case against Merck & Co. over deceptive marketing for the drug Vioxx. The state lead a three-year investigation into Merck's deceptive advertisements downplaying the health risks associated with Vioxx. The...

  • Merck Lesson: Risk Needs Rebranding. Edwards, Jim // Brandweek;11/7/2005, Vol. 46 Issue 40, p22 

    Discusses the issues surrounding the victory of pharmaceutical firm Merck during the trial filed against it for marketing the drug Vioxx in 2005. Lessons learned from the trial; Effect of the trial on the U.S. pharmaceutical industry; Efforts of several pharmaceutical firms to restore the faith...

  • Merck, Dow Scolded Over Promotions.  // BioWorld Today;3/12/2012, Vol. 23 Issue 48, p4 

    The article reports on the reminder given by the U.S. Food and Drug Administration (FDA) to Dow Pharmaceuticals Sciences Inc. and Merck and Co. Inc. that letters from the FDA Office of Prescription Drug Promotion (OPDP) urge them to task over their drug promotions.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics